New Defense Health Agency guidelines require clinicians to discuss fertility goals before prescribing testosterone therapy for male service members.
On September 17, 2026, the Defense Health Agency issued a new Clinical Practice Guideline for Testosterone Deficiency in the Male Service Member. This policy introduces structured screening measures and explicitly requires clinicians to address patient fertility goals before prescribing exogenous hormone treatments.
The content provided in this article is strictly for informational and educational purposes. It does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider regarding individual health concerns or before starting any new medical intervention.
The foundation for this new screening policy originated from a memorandum issued in July 2026. This initial directive mandated screening for service members aged 30 and older during periodic health assessments. The screenings also take place during entry to the military or during annual physical examinations.
The Defense Health Agency structured this first evaluation step as a comprehensive symptom and risk-factor assessment, rather than relying on an automatic laboratory blood test. By beginning with a structured clinical interview, the policy aims to identify men who are actually experiencing physical changes before drawing blood. For men under the age of 30, the policy states that screening may occur upon patient request or when a medical provider identifies specific clinical indicators that warrant further investigation.
Reporting from Military.com outlines the rigorous diagnostic pathway established under these new military guidelines. A positive initial screening does not guarantee a prescription but instead leads to specific laboratory testing protocols. Clinicians must confirm a pattern of consistent symptoms alongside two separate fasting morning testosterone measurements. Both of these morning testosterone blood draws must fall below the established threshold of 300 ng/dL.
The numerical reading alone is strictly insufficient for a diagnosis. This rule ensures that treatment decisions rely on a comprehensive clinical picture rather than a single isolated metric. A temporary dip in hormone levels can happen for many lifestyle reasons, making a single test unreliable. By requiring two separate tests, the policy minimizes the risk of treating a temporary fluctuation.
Furthermore, the second blood draw must include dedicated testing for luteinizing hormone and follicle-stimulating hormone. These additional biomarkers provide vital context for the primary physician. They help the medical team determine whether the low testosterone originates from a failure in the testes or a signaling issue in the brain.
A central element of the new military guideline is a mandatory conversation regarding reproductive goals before initiating any hormone therapy. According to Military.com, externally supplied testosterone can actively suppress the biological signals that naturally support hormone and sperm production in the male body. Because of this well-documented biological reality, a service member who wants children or remains undecided should not begin standard exogenous testosterone.
Instead, the guideline directs medical professionals toward alternative interventions like human chorionic gonadotropin, which mimics the natural signals that stimulate the testes to produce testosterone and sperm. Off-label use of clomiphene citrate is also explicitly listed as an alternative option for preserving testicular function. Standard testosterone replacement remains a direct option primarily for service members who clearly state they do not desire children, or who have already completed their families and no longer require fertility preservation.
This military policy functions as a service-specific clinical guideline, and it currently applies exclusively to male service members. The Defense Health Agency has indicated that separate guidance addressing female service members is planned for the future. Additionally, these directives do not dictate a new universal standard of care for civilian medical practices.
The Defense Health Agency's public announcement presents the entire initiative as a measure supporting overall military readiness. The department frames testosterone replacement or other hormone treatments as potential options to maintain service member health and operational capability. All treatment plans are strictly monitored and adjusted by military medical professionals. The goal is to ensure that medical interventions support the physical demands placed on service members safely.
While human chorionic gonadotropin provides an alternative to standard testosterone therapy, it is not a foolproof mechanism for preserving fertility. The Endocrine Society issued specific scientific cautions regarding its use as a universal safeguard. The organization noted that human chorionic gonadotropin can actually suppress follicle-stimulating hormone. This suppression may reduce sperm production and overall fertility in men experiencing obesity-induced hypogonadism, a demographic that typically presents with normal follicle-stimulating hormone levels initially.
Furthermore, the Endocrine Society highlighted the risks associated with prolonged timelines on complex treatment protocols. The organization warned that patients using a combination of testosterone replacement and human chorionic gonadotropin face potential reproductive delays. After two or more years on this combined regimen, the recovery of normal sperm and natural hormone production may experience significant functional delays.
Independent endocrinologists and medical professionals have reviewed the military framework, providing mixed reactions to its clinical components. Dr. Haleem Mohammed, identified by Military.com as the chief medical officer of Gameday Men's Health, strongly emphasized the critical nature of the guideline's required fertility questions. He stated that fertility was his biggest concern when evaluating potential patients for any form of hormone therapy.
From his clinical perspective, men who want children or remain undecided simply would not start standard testosterone outright. He noted that utilizing alternative treatments like human chorionic gonadotropin helps these men continue making sperm, preserving their reproductive capacity while addressing their hormonal symptoms.
Dr. Mohammed also provided context from his own civilian clinic practice, illustrating a cautious approach to immediate treatment. He shared that roughly half of the men presenting with low testosterone at his clinic initially wait for treatment. During this period, potential reversible lifestyle causes are addressed, and patients learn to prepare for a testosterone test to verify their baseline hormone status. This observational window ensures that patients do not rush into medical interventions unnecessarily.
The Endocrine Society raised separate, significant objections concerning the guideline's specific approach to obesity-related low testosterone. The organization criticized the framework for offering standard testosterone replacement alongside weight-management care. The Endocrine Society maintains that weight management should remain the primary focus for obesity-induced hypogonadism.
The organization argues against introducing exogenous hormones simultaneously with lifestyle interventions. Weight loss alone can often restore natural hormone production in this specific patient population. They warned that the complex biological relationship between obesity, hormone signaling, and fertility requires highly individualized, sequential management. Overlapping treatments might complicate the clinical picture and obscure the root cause of the hormone deficiency.
These updated military directives highlight a critical biological reality for men considering hormone therapy today. Externally supplied testosterone clearly impacts reproductive signaling, making an early and honest discussion about family planning essential. For men weighing hormone treatment against current or future fertility, identifying reproductive goals must happen before any therapy begins. Patients should actively ask their clinicians how any proposed plan might affect sperm production, what alternative interventions exist, and how testosterone replacement therapy works over the long term.
The conversation around fertility preservation is highly nuanced and highly individual. While alternative therapies exist, they require careful monitoring and do not offer universal protection against reproductive changes. A patient who fully understands these physiological trade-offs can navigate treatment decisions with greater confidence. Gathering detailed information beforehand prevents unexpected complications down the road.
The new guideline also reinforces a fundamental principle of diagnostic medicine. A single low testosterone result does not automatically justify medical intervention, nor does it guarantee a diagnosis. Clinicians must evaluate low testosterone symptoms in their clinical context alongside two separate fasting morning testosterone measurements.
While civilian doctors are not strictly bound by military protocols, the Defense Health Agency framework provides a structured example of how to approach hormone health responsibly. The emphasis remains on thorough testing, clear symptom evaluation, and transparent conversations about the long-term biological trade-offs of hormone replacement. Men outside the military can use these same principles to guide discussions with their own healthcare providers.
When evaluating clinical guidelines and balancing treatment options against future fertility goals, understanding individual hormone data requires reliable context. Testostra steps in when readers face confusion around TRT evidence, risks and monitoring. We provide an educational foundation that helps adult men interpret clinical research without exaggeration, ensuring they can ask better questions during medical consultations. Read Resources
Testostra follows testosterone research, clinical guidance and emerging evidence without turning general information into personal treatment advice.
Send us a question, research idea or topic suggestion. Reader questions help shape future Testostra content.
Contact Testostra